Development of At-211 labeled peptides for the targeted alpha therapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461872
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: National Institutes for Quantum and Radiological Science and Technology (2016); Japan Atomic Energy Agency (2014-2015)
• Principal Investigator: Watanabe Shigeki 国立研究開発法人量子科学技術研究開発機構, 高崎量子応用研究所 放射線生物応用研究部, 主幹研究員(定常) (10450305)
• Co-Investigator(Renkei-kenkyūsha): Ohshima Yasuhiro 国立研究開発法人量子科学技術研究開発機構, 高崎量子応用研究所 放射線生物応用研究部, 主任研究員 (00588676)
• Research Collaborator: Sasaki Ichiro 国立研究開発法人量子科学技術研究開発機構, 高崎量子応用研究所 放射線生物応用研究部, 任期制技術員
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: At-211 / 内用放射線治療 / アルファ線 / ペプチド

Outline of Final Research Achievements

The use of alpha emitting radionuclides has been promising for development of targeted radionuclide therapy (TRT) because alpha particles give heavier damage to the cell by smaller dose than beta particles which has been employed for the TRT. In this study, we have successfully developed a novel isolation method of alpha emitting astatine-211 from an irradiated Bi target, and At-211 labeled peptides which have high affinity to HER2 overexpressing in some cancer cells such as breast cancer.

Free Research Field

放射化学